The effects of telmisartan and hydrochlorothiazide (HCTZ) alone and in combination on blood pressure (BP) and renal excretory function were investigated in male spontaneously hypertensive rats (SHR) after oral administration for five consecutive days. Four treatments were studied: vehicle (0.5% Natrosol™), telmisartan 3 mg/kg, HCTZ 10 mg/kg, and telmisartan 3 mg/kg+ HCTZ 10 mg/kg. The effects on BP and heart rate were studied in 40 SHRs (10 animals per group) using an implanted telemetry device. Renal excretory function was assessed in 76 SHRs (18 animals per group, of which nine were used for urine sampling and nine for blood sampling).
Introduction
Thiazide diuretics, such as hydrochlorothiazide (HCTZ), are widely used for the clinical management of hypertension. These agents exert their antihypertensive activity by eliminating water and sodium from the body. However, the resultant reduction in plasma volume leads to a reflex activation of the renin-angiotensin system (RAS). In turn, increased circulating angiotensin II (Ang II) levels cause vasoconstriction and promote water and sodium retention, effects that directly oppose the antihypertensive activities of the diuretic. Furthermore, chronic diuretic treatment is associated with various adverse metabolic disturbances, such as potassium depletion, [1] [2] [3] which prevent the long-term use of these agents at high doses.
Since many of the limiting effects of diuretic therapy are mediated by Ang II, concomitant administration of agents that interfere with the RAS may prevent or attenuate these adverse effects, thereby allowing the full potency of the diuretic to be realised. For example, clinical studies have shown that angiotensin-converting enzyme inhibitors (ACE-I) enhance the antihypertensive efficacy of diuretics and blunt or prevent adverse metabolic effects. 4 The combination of an Ang II antagonist with HCTZ appears to confer similar benefits. 5, 6 Telmisartan is a new, orally active, non-peptide antagonist of the Ang II AT 1 -receptor, which has been developed for the treatment of hypertension. 7 In addition to its vasodilatory properties, 8 telmisartan appears to exert a further antihypertensive effect by directly modulating renal excretory function. For example, telmisartan augmented frusemide-induced increases in renal perfusate, glomerular filtration rate and urinary flow in a dose-dependent manner in isolated rat kidneys. 9 The drug has also been shown to promote the renal excretion of water, sodium (Na + ) and chloride (Cl -) without affecting potassium (K + ) excretion in normotensive anaesthetised rats and normotensive conscious dogs after intravenous or oral administration. 9, 10 Treating hypertension with a combination of an Ang II antagonist and HCTZ, therefore, has a 3fold rationale. Firstly, HCTZ-induced activation of the RAS augments its role in blood pressure (BP) regulation, thereby amplifying the effects of agents that act through RAS blockade, such as Ang II antagonists. Secondly, inhibition of the actions of Ang II may be expected to reverse or attenuate some of the adverse metabolic consequences of HCTZ treatment, such as potassium depletion. Thirdly, when combined with a second antihypertensive with a complementary mechanism of action, a low dose of HCTZ may be adequate to achieve BP control, thereby reducing the risk of metabolic disturbances.
In the present study, we investigated the effects of telmisartan and HCTZ, as monotherapies or in combination, on BP and renal excretory func-tion in conscious spontaneously hypertensive rats (SHRs) after once-daily oral administration on five consecutive days.
Methods

Treatments
Four treatments were examined: vehicle (0.5% Natrosol™), telmisartan monotherapy (3 mg/kg), HCTZ monotherapy (10 mg/kg) and telmisartan/ HCTZ combination therapy (telmisartan 3 mg/ kg+HCTZ 10 mg/kg). Telmisartan and HCTZ were prepared as 0.5% Natrosol™ suspensions. All treatments were administered once-daily at a volume of 2 ml/kg p.o. for five consecutive days (days 1-5).
Experimental animals
Male SHRs (Charles River, Sulzfeld, Germany), weighing approximately 300 g, were used for all procedures. Animals were housed individually in Macrolon cages. The light-dark cycle in the housing room was reversed (artificially illuminated from 6.00 p.m. to 6.00 a.m.) so that the main activity phase of these nocturnal animals coincided with the time of study drug administration (between 8.20 a.m. and 8.50 a.m.). Animals were adapted on this light-dark cycle for more than four weeks prior to the study. Drinking water was freely available to the rats throughout the experimental period, and animals were fed on standard laboratory chow.The effects of the four different treatments on BP and heart rate were assessed in a total of 40 animals (10 rats per treatment group); the effects on urinary and blood parameters were assessed in 76 animals (18 rats per treatment group).
Blood pressure and heart rate measurements
Several weeks before study initiation, a chronicuse telemetry device was implanted into each experimental animal. Each rat was anaesthetised with pentobarbitone sodium (50 mg/kg, i.p.), and the abdominal cavity was opened with a midline incision. The catheter of a pressure inducer (RA11PA-C40; Data Sciences Inc., St Paul, MN, USA) was inserted into the abdominal aorta and the transmitter fixed to the abdominal musculature. The abdomen was then closed with Mersilene™ sutures. Animals were allowed to recover for several weeks after the procedure.
BP and heart rate were transmitted by telemetry and the signals were received by an RA 1010 General Purpose Receiver (Data Sciences Inc., St Paul, MN, USA). Data were acquired with the Dataquest IV 1.21 System on a Dell computer. Analysis of data was performed using a software package that had been developed in-house. Baseline BP measurements in all treatment groups were taken within a 30-minute period at trough, prior to administration of study medication. This period was considered to be short enough to avoid differences between treated and untreated animals. Values were sampled at a rate of 250 Hz for 5 seconds every 10 minutes throughout the experimental period. Diastolic BP (DBP), systolic BP (SBP), mean BP (mBP) and heart rate data were collected continuously from day -3 to day 15 (i.e. until 10 days after administration of the final dose of treatment). Because of the specific computer system configuration and the in-house statistical programme, acquired data were averaged over intervals of 3 hours.
Assessment of renal function
Eighteen SHRs were allocated to each treatment group; nine rats were used for urine sampling, and the remaining nine for blood sampling. All animals received a tap water load of 2 ml/100 g by gavage before study drug administration, and those used for urine collection were housed in metabolic cages. Urine and blood was collected on day -1 (pretreatment), day five and day 14 at 4 hours (T4 hour), 8 hours (T8 hour) and 24 hours (T24 hour) after the administration of study medication. All samples were taken serially from the same animal on the different days during the experimental period.
Urine volume, pH, electrolytes (Na + , Cland K + ) and markers of renal function (creatinine, microprotein and glucose) were measured in urine samples collected over the time periods T0-T4 hour, T4-T8 hour, and T0-T24 hour. Serum concentrations of Na + , Cl -, K + , creatinine, glucose and blood urea nitrogen (BUN) were determined in blood samples drawn at T4 hour,T8 hour and T24 hour.
All assays were performed using a Beckman Clinical System Synchron CX5 CE (Beckman Instruments Inc., Diagnostics Systems Group, Brea, CA, USA). Concentrations of Na + , Cland K + were determined from electrolyte activity in solution using ion-selective electrodes, and levels of creatinine were measured by a modified rate Jaffé method. Glucose concentrations were also assessed by a timed endpoint method and an enzymic rate technique was used for BUN quantification.
Statistical analysis
Data for DBP, SBP, mBP and heart rate are expressed as mean±standard error of mean (SEM). Measurements recorded prior to drug administration were averaged to represent baseline values. All other data for each active treatment group are presented as mean changes from baseline values at trough (i.e. 24 hours after administration of the previous dose). A one-way analysis of variance (ANOVA), Dunnett's test and Tukey-Kramer horizontal comparison test were used to detect between-group differences, with p<0.05 being considered statistically significant.
Measurements of urine and blood parameters are presented as mean ± standard deviation (SD). Between-group comparisons of these data were conducted using an ANOVA for each observation time. A post-hoc Dunnett's test was used to compare the various active treatment groups with vehicle when the ANOVA indicated significance. p<0.01 was considered statistically significant. (Table 1 ). After administration of the first dose of telmisartan, 3 mg/kg, however, significant reductions were produced in trough DBP, SBP and mBP compared with vehicle-treated controls (p<0.05; Figure 1a -c). BP continued to decline with each successive dose of telmisartan, the greatest decreases from baseline levels being observed after administration of the final dose: -31±1.1 mmHg for DBP, -39±2.0 mmHg for SBP, and -36±1.6 mmHg for mBP. All BP parameters increased gradually to baseline levels during the post-treatment observation period, with no evidence of rebound hypertension. Telmisartan 3 mg/kg+HCTZ 10 mg/kg combination therapy lowered BP to an even greater extent than telmisartan monotherapy ( Figure  1a -c). The decline in BP in telmisartan/HCTZtreated SHRs was also progressive, with maximum reductions in DBP (-44±1.5 mmHg), SBP (-60±1.9 mmHg) and mBP (-53±1.7 mmHg) from baseline levels being achieved on day six (i.e. 24 hours after administration of the last dose). Furthermore, throughout the treatment period, the decreases in trough DBP, SBP and mBP produced by telmisartan/HCTZ combination therapy were significantly greater than those produced by telmisartan alone Analysis of BP measurements revealed a diurnal pattern with peak levels occurring during the daytime and trough levels in the morning (resulting from the reversed light-dark cycle). In control animals, the maximum difference between peak and trough BP values amounted to 10-15 mmHg. The circadian rhythm was maintained in treated animals.
Results
Blood pressure and heart rate
The changes in heart rate among SHRs receiving telmisartan or HCTZ monotherapy did not differ significantly from those receiving vehicle. In contrast, the telmisartan/HCTZ combination led to a moderate elevation in heart rate by a maximum of 12±3 beats per minute compared with baseline. When compared with the time-matched vehicletreated group, this effect was statistically significant (p<0.05). This increase in heart rate was no longer apparent after treatment cessation.
Renal function
Urine volume, pH, and concentrations of electrolytes, creatinine, microprotein and glucose were similar among all four treatment groups at baseline and during the post-treatment observation period.
The effects of the various treatments on urine excretory parameters at the end of the 5-day treatment period are shown in Table 2 . Significant increases in urine volume and Na + , K + , Cl -, creati-nine and glucose excretion were observed in the samples collected over T0-T4 hour in HCTZ-treated SHRs compared with vehicle-treated animals (p<0.01). Urine collected over the entire 24-hour period (T0-T24 hour) from rats on HCTZ monotherapy also contained significantly higher concentrations of Na + , K + and Clthan controls (p<0.01).
The telmisartan/HCTZ combination produced statistically significant increases in urine volume and renal excretion of Na + , Cland K + . The effect on urine volume was greater than with HCTZ alone, but some attenuation of HCTZ-associated K + electrolyte excretion could be observed. Urinary excretion of creatinine and glucose in SHRs treated with the telmisartan/HCTZ combination remained at baseline levels. A reduction in urine pH was seen in all treatment groups over the 24hour post-dose period in samples collected on day -one, day five and day 14.
Telmisartan monotherapy did not produce any significant alterations in urine excretory parameters compared with vehicle treatment. Small increases in urine volume and Clexcretion were recorded, but these did not reach statistical significance.The level of microprotein in the urine was not influenced by any of the study treatments.
In general, the administration of telmisartan, HCTZ or telmisartan/HCTZ combination therapy for five days did not affect the parameters measured in serum. An exception was BUN, which was increased significantly in samples collected at T8 h and T24 hour from SHRs treated with HCTZ (9.04±0.73 and 9.88±0.87 mmol/l, respectively) or telmisartan/HCTZ (9.23±0.79 and 9.18±0.79 mmol/l, respectively) compared with vehicletreated animals (7.69±1.07 and 7.38±0.58 mmol/l, respectively) (p<0.01). The significant increase in PAPER creatinine excretion observed with HCTZ over T0-T4 hour was not accompanied by an increase in serum creatinine levels: in the T4-hour blood sample, serum creatinine concentration was 50.4±4.3 µmol/l on day -one and 53.6±4.9 µmol/l on day five. Mean creatinine excretion over the T0-T24 hour period was not elevated by HCTZ treatment.
Discussion
The current study has shown that the antihypertensive efficacy of telmisartan in SHRs is amplified by co-administration with HCTZ after five days of once-daily oral treatment. Furthermore, the combination of telmisartan and HCTZ did not have any significant effect on renal excretory function with the exception of increasing BUN, a characteristic consequence of HCTZ administration. There was also some indication that telmisartan/HCTZ combination treatment ameliorated the alteration in potassium balance that is commonly associated with thiazide diuretic therapy. From a clinical perspective, these results suggest that telmisartan/ HCTZ combination therapy may confer greater BP reductions in hypertensive patients than singleagent therapy while minimising the risk of potassium depletion.
Our findings also demonstrate that telmisartan is a powerful antihypertensive agent in SHRs. This confirms previous reports, 11 and is in agreement with studies investigating the effects of other Ang II antagonists on BP in SHRs. 12, 13 Significant reductions in BP following telmisartan treatment have also been reported in various other animal models of hypertension, including transgenic TGR(mREN2) 27 rats and SHRs of the stroke-prone strain. [14] [15] [16] The administration of telmisartan in combination with HCTZ produced greater reductions in DBP, SBP and mBP in SHRs compared with telmisartan alone.This potentially synergistic effect of the two drugs can be attributed to their complementary mechanisms of action.Antihypertensive agents that cause compensatory activation of the RAS, such as HCTZ, increase circulating Ang II levels.As a consequence, the antihypertensive actions of agents that act by blocking the haemodynamic actions of Ang II, such as AT 1 -receptor antagonists and ACE-I, are augmented. Consistent with this explanation is the observation that both captopril plus HCTZ and candesartan cilexetil plus HCTZ produce greater BP reductions in SHRs than captopril or candesartan cilexetil alone. [17] [18] [19] The additive effect of telmisartan/HCTZ combination treatment on BP is supported by findings from a clinical trial which evaluated, using a factorial design, the antihypertensive efficacy of various dose combinations of telmisartan and HCTZ vs. the individual monotherapies in patients with mild-tomoderate hypertension. 6 Combinations of telmisartan 80 mg/HCTZ 12.5 mg and telmisartan 40 mg/HCTZ 12.5 mg produced clinically relevant decreases in SBP and DBP, which were significantly greater than those achieved with either drug alone. Similar observations have been reported when HCTZ is co-administered with other AT 1 -receptor antagonists, including losartan, valsartan, irbesartan, eprosartan, and candesartan cilexetil. 5, [20] [21] [22] [23] A further clinically relevant finding of the current study was that over the post-treatment observation period, BP in the telmisartan and telmisartan/HCTZ groups returned gradually to baseline levels, indicating that interruption or cessation of these treatments would not be expected to result in complications such as rebound hypertension.
Interestingly, HCTZ alone did not decrease BP in the SHR model in the present experiments. Other authors have reported comparable findings. For example, Lai et al. treated SHRs for two days with HCTZ at oral doses of 100 mg/kg on day one and 10 mg/kg on day two. 19 Mean arterial BP in these animals was not reduced, but plasma renin activity increased 3-fold. A possible explanation for the failure of HCTZ to lower BP in SHRs, therefore, could be that the diuretic and natriuretic effects of HCTZ are outweighed by a massive stimulation of the RAS, resulting in pronounced and opposing vasoconstriction.
The reason for the slight, but significant, increase in heart rate induced by telmisartan/HCTZ treatment, when compared with telmisartan monotherapy, is currently unclear.While it is generally accepted that ACE-I and Ang II antagonists do not cause reflex tachycardia, the data in the literature are not uniform. In some studies, treatment of SHRs with agents from these classes did not affect heart rate, 12, 17 whereas in others, a small increase of approximately 20 beats per minute was detected. [24] [25] It should be pointed out, however, that the telmisartan/HCTZ combination induced a significantly greater reduction in BP than monotherapy, suggesting that the increase in heart rate may be the result of disproportional reflex activation of the sympathetic nervous system.
The increase in urine volume over the 24-hour post-dose period with telmisartan/HCTZ combination therapy was greater than with HCTZ treatment alone. Augmentation of the diuretic response may be due, at least in part, to an increase in glomerular filtration rate following blockade of vascular AT 1receptors by telmisartan in the kidney, causing vasodilation. In support of his hypothesis is the finding that telmisartan improves glomerular filtration rate in the isolated rat kidney. 9 Furthermore, a slight diuretic effect was noted with telmisartan monotherapy in the current study and has also been reported in experiments involving conscious dogs and anaesthetised rats. 9, 10 The addition of telmisartan to HCTZ also appeared to exert a favourable effect on the renal excretion of K + compared with HCTZ alone. The concentration of K + in the urine of animals receiving telmisartan/HCTZ was not significantly different from those receiving vehicle over the T4-T8 hour and T0-T24 hour collecting periods, despite an acute elevation in excretion between T0 hour and T4 hour. Thus, these findings suggest that telmisartan may attenuate the potassium loss associated with HCTZ treatment.
Of the serum parameters measured, only BUN was altered by active treatment. Unsurprisingly, administration of HCTZ, either alone or in combination with telmisartan, led to a significant increase in BUN levels compared with vehicletreated controls, which is consistent with the known effects of thiazide diuretics on uric acid metabolism. Hyperuricaemia occurs secondary to a reduction in glomerular filtration rate and inhibition of uric acid secretion resulting from competition between organic acid and diuretic at the renal tubule. 26 Volume depletion also enhances uric acid reabsorption in the proximal tubule. 26 Finally, a time-related decrease in urine pH was observed in all treatment groups at all time points. This change is likely to be related to starvation, either directly or indirectly, through the induction of a catabolic state.
Taken together, the findings of this study show that, in the SHR experimental model of essential hypertension, a combination of telmisartan with HCTZ exerts greater antihypertensive efficacy than the individual agents alone. This is accompanied by minor changes in heart rate and potentially favourable effects on renal excretory function. From a clinical perspective, these results suggest that telmisartan/HCTZ combination therapy may confer greater BP reductions in hypertensive patients than single-agent therapy, while minimising the risk of adverse metabolic disturbances associated with HCTZ treatment, such as potassium depletion.
